BGSI vs COLL vs AVDL vs HRMY

For growth investors, Avadel Pharmaceuticals plc (AVDL) is the stronger pick with 504.

8% revenue growth year-over-year, versus 4. 2% for Boyd Group Services Inc. (BGSI). Harmony Biosciences Holdings, Inc. (HRMY) offers the better valuation at 11. 1x trailing P/E (8. 4x forward), making it the more compelling value choice. Analysts rate Boyd Group Services Inc. (BGSI) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Harmony Biosciences Holdings, Inc.

(HRMY) is the cheapest at 11. 1x versus Boyd Group Services Inc. at 134. 5x. On forward P/E, Collegium Pharmaceutical, Inc. is actually cheaper at 4. 8x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Avadel Pharmaceuticals plc (AVDL) delivered a total return of +162.

9%, compared to -23. 9% for Boyd Group Services Inc. (BGSI). Over 10 years, the gap is even starker: AVDL returned +145. 1% versus BGSI's -23. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Avadel Pharmaceuticals plc (AVDL) is the lower-risk stock at 0.

19β versus Boyd Group Services Inc. 's 0. 82β — meaning BGSI is approximately 338% more volatile than AVDL relative to the S&P 500. On balance sheet safety, Avadel Pharmaceuticals plc (AVDL) carries a lower debt/equity ratio of 2% versus 3% for Collegium Pharmaceutical, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Avadel Pharmaceuticals plc (AVDL) is pulling ahead at 504.

8% versus 4. 2% for Boyd Group Services Inc. (BGSI). On earnings-per-share growth, the picture is similar: Avadel Pharmaceuticals plc grew EPS 74. 5% year-over-year, compared to -27. 2% for Boyd Group Services Inc.. Over a 3-year CAGR, HRMY leads at 25. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Harmony Biosciences Holdings, Inc.

(HRMY) is the more profitable company, earning 18. 3% net margin versus -28. 9% for Avadel Pharmaceuticals plc — meaning it keeps 18. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BGSI leads at 92. 2% versus -25. 1% for AVDL. At the gross margin level — before operating expenses — AVDL leads at 91. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Collegium Pharmaceutical, Inc.

(COLL) trades at 4. 8x forward P/E versus 28. 3x for Avadel Pharmaceuticals plc — 23. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for COLL: 62. 5% to $58. 00.

In this comparison, BGSI (0.

4% yield) pays a dividend. COLL, AVDL, HRMY do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Avadel Pharmaceuticals plc (AVDL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

19), +145. 1% 10Y return). Both have compounded well over 10 years (AVDL: +145. 1%, BGSI: -23. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BGSI (Consumer Cyclical) and COLL (Healthcare) and AVDL (Healthcare) and HRMY (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BGSI is a small-cap quality compounder stock; COLL is a small-cap high-growth stock; AVDL is a small-cap high-growth stock; HRMY is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.